According to other research findings, combining PI3K/AKT/mTOR inhibitors with ICIs (which include PD-1 inhibitors in parallel with CTLA-4 inhibitors) or other anti-tumor immunotherapy may enable patients to obtain the best efficacy [91]. The gene discussed is PIK3CA; the disease is neoplasm.